First-line bortezomib benefits patients with multiple myeloma

Nature Reviews Clinical Oncology

Volumn 6, Issue 12, 2009, Pages 683-685

  Dimopoulos, Meletios A ^a   Terpos, Evangelos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BORTEZOMIB; CARNITINE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FOLIC ACID; GABAPENTIN; GLUTAMINE; LENALIDOMIDE; MAGNESIUM; MELPHALAN; PREDNISOLONE; THALIDOMIDE; THIOCTIC ACID; VINCRISTINE; VITAMIN B COMPLEX; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROMYOGRAPHY; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SHORT SURVEY; SKIN BIOPSY; SYMPTOM; TREATMENT DURATION; NOTE; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES;

EID: 75649129122     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2009.171     Document Type: Short Survey

References (10)

1. Richardson, P G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 352, 2487-2498 (2005).
2. Terpos, E. et al. Bortezomib In multiple myeloma. Expert Opin. Drug Metab. Toxicol. 4, 639-654 (2008).
3. San Miguel, J. F. et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N. Engl. J. Med. 359, 906-917 (2008).
4. Pineda-Roman, M. et al. Sustained complete remissions In multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br. J. Hematol. 140, 625-634 (2008). (Pubitemid 351300910)
5. Richardson, P G. et al. Single-agent bortezomib In previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J. Clin. Oncol. 27, 3518-3525 (2009).
6. Harousseau, J. L. et al. Bortezomib plus dexamethasone as induction treatment before autologous stem cell transplantation In patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Hematologica 91, 1498-1505 (2006).
7. Harousseau, J. L. et al. Bortezomib/ dexamethasone versus VAD as induction before autologous stem cell transplantion (ASCT) In previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J. Clin. Oncol. 26 (Suppl.), 8505 (2008).
8. Cavo, M. et al. Bortezomib (Velcade)thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) In preparation for autologous stem-cell (SC) transplantation (ASCT) In newly diagnosed multiple myeloma (MM) [Abstract 73]. Blood 110 (Suppl.), 30a (2007).
9. England, J. D. et al. Distal symmetric polyneuropathy: a definition for clinical research. Report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 64, 199-207 (2005).
10. Hulin, C. et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J. Clin. Oncol. 27, 3664-3670 (2009).